Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a specific reporting date of February 17, 2022. The document serves as a transaction notification regarding the granting of awards under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) to Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data presented relates to the valuation of specific equity awards granted to executives on February 15, 2022:
- Ordinary Shares Price: GBP 15.712 per share.
- American Depositary Shares (ADS) Price: USD 42.87 per ADS.
- Total Awards Granted: The filing details individual share/ADS volumes for 14 executives, ranging from 2,482 ADSs to 72,399 Ordinary Shares.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents the execution of a pre-approved compensation plan (DABP) where Executive Directors defer 50% of bonuses and other Leadership Team members defer 25% into shares or ADSs for a three-year period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a regulatory disclosure of a specific corporate action (bonus deferral awards) rather than a financial results report.
Investor Verification Checklist
- Verify the total number of shares and ADSs issued to PDMRs against the company's latest equity compensation plan disclosures.
- Confirm the share price used for the awards (GBP 15.712 / USD 42.87) aligns with market prices on February 15, 2022.
- Review the terms of the 2017 Deferred Annual Bonus Plan to understand the vesting schedule and dividend reinvestment rights.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F or quarterly reports for those metrics.